Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “VASOPRESSIN”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,585 records · Page 88Linked to original sources
PubMed1988

Involvement of a plasma membrane phosphodiesterase in the negative control of cyclic AMP levels by vasopressin in rat hepatocytes.

Vasopressin has been shown previously to lower the glucagon-induced increase of cyclic AMP levels in isolated rat hepatocytes by way of an enhanced phosphodiesterase (EC 3.1.4.17) activity. Five phosphodiesterase inhibitors were tested for their ability to prevent vasopressin from lowering cyclic AMP levels in intact hepatocytes and for their inhibitory effect in vitro on soluble and particulate phosphodiesterase activities partially purified from hepatocytes. Three soluble activities have been separated by DEAE-cellulose chromatography: a phosphodiesterase hydrolyzing both cyclic AMP and cyclic GMP, a form stimulated by cyclic GMP and a cyclic AMP-specific activity. The absence of any statistically significant correlation between the in vivo (in intact cells) and the in vitro (on isolated phosphodiesterases) potencies of the inhibitors does not support a role for the cytosolic phosphodiesterases in mediating the vasopressin-induced decrease in cyclic AMP levels. No statistically significant correlation was observed between the inhibition of the vasopressin effect on cyclic AMP accumulation and the inhibition of phosphodiesterase activity either associated with the native plasma membranes or solubilized from these membranes with 0.4 M NaCl. In contrast, a statistically significant correlation was observed between the degree of inhibition of the vasopressin effect in the intact cells and the degree of inhibition of the intrinsic phosphodiesterase still associated with the plasma membranes after high-salt treatment. These data indicate that a phosphodiesterase activity integral to the plasma membrane is very likely involved in the negative control of cyclic AMP levels by vasopressin.

Animals↗
PubMed1988

Effects of quinacrine on vasopressin-induced changes in glycogen phosphorylase activity, Ca2+ transport and phosphoinositide metabolism in isolated hepatocytes.

In isolated hepatocytes, quinacrine (150-250 microM) inhibited vasopressin-induced increases in glucose release, glycogen phosphorylase a activity and 45Ca2+ efflux; and glucagon-induced increases in glucose release and cyclic AMP formation. These results indicate that a phospholipase A2 enzyme sensitive to quinacrine is unlikely to be involved in the process by which vasopressin stimulates glycogen phosphorylase activity in the liver cell. In cells labelled with [3H]inositol, much lower concentrations of quinacrine (20-50 microM) inhibited the stimulation by vasopressin of the accumulation of [3H]inositol. The drug had little effect on vasopressin-induced accumulation of [3H]inositol mono-, bis- and tris-phosphates. In the absence of vasopressin, higher concentrations of quinacrine caused a small stimulation of glycogen phosphorylase activity, 45Ca2+ release and the formation of [3H]inositol polyphosphates. Quinacrine did not inhibit the degradation by liver homogenates of inositol 1-phosphate, inositol 4,5-bisphosphate or inositol 1,4,5-trisphosphate. It is concluded that concentrations of quinacrine comparable with those which inhibit phospholipase A2 [G.J. Blackwell, W.G. Duncombe, R.J. Flower, M.F. Parsons and J.R. Vane, Br. J. Pharmac. 59, 353-366 (1977)] inhibit the stimulation by vasopressin of inositol utilization without significantly affecting coupling between hormone receptors and adenyl cyclase or phosphoinositide-specific phosphodiesterase, the action of the phosphodiesterase, and the degradation of inositol triphosphate.

Animals↗
PubMed1978

Comparison of firing patterns in oxytocin- and vasopressin-releasing neurones during progressive dehydration.

The electrical activity of neurosecretory cells in the supraoptic nucleus of the urethane-anaesthetized lactating rat was examined after periods of water deprivation ranging from 0-24 h. Supraoptic units were identified by antidromic activation following stimulation of the neurohypophysis, and classified as oxytocin or vasopressin cells according to their response during reflex milk ejection. In 65 vasopressin cells, dehydration increased the mean firing rate from 2.1 spikes/sec at 0 h to 6.8 spikes/sec at 24 h and caused a change from a slow irregular to a phasic firing pattern. Thus, after 6 h or more of dehydration, 84-100% of the vasopressin cells fired phasically, compared to 12% under normal conditions. In phasic vasopressin cells , the intraburst firing rates were closely related to the stages of dehydration, rising from a mean of 6.3 spikes/sec at 6 h to 12.0 spikes/sec at 24 h. However, no systematic relationship was observed between the stages of dehydration and the mean burst or silence durations. In 77 identified oxytocin units, dehydration increased the firing rate from 0.9 spikes/sec to 2.8 spikes/sec after 24 h, but only 3 (4%) of the cells showed phasic firing. Instead, the oxytocin units changed from a slow irregular to a fast continuous discharge. In conclusion, both vasopressin and oxytocin neurones are activated during chronic dehydration, but there is a marked difference in the pattern of their response. The phasic firing of the vasopressin cells may be important in increasing the occurrence of short interspike intervals and thus facilitating hormone release.

Action Potentials↗
PubMed1983

High histamine levels in specific hypothalamic nuclei of Brattleboro rats lacking vasopressin.

Histamine levels were determined in whole hypothalamus and specific hypothalamic nuclei of male 9-week-old homozygous Brattleboro rats lacking vasopressin and presenting the syndrome of diabetes insipidus (DI rats). These levels were compared to those in heterozygous Brattleboro rats with a partial deficit in vasopressin (HZ rats) and those in Long Evans control rats (LE rats). In whole hypothalamus, histamine levels in DI rats were higher than those found in HZ and LE rats. DI rats showed histamine levels higher than those present in LE rats in the nuclei supraopticus, paraventricularis and suprachiasmatis and in the area retrochiasmatica. Vasopressin replacement produced a selective decrease in histamine levels of DI rats, restricted to the area retrochiasmatica and nuclei supraopticus and paraventricularis. In contrast, vasopressin increased histamine levels in the area retrochiasmatica and eminentia mediana of HZ rats. In other areas normally rich in vasopressin such as the nucleus arcuatus and the eminentia mediana, the histamine content was not different among LE, HZ or DI rats. Our results suggest a physiological interaction between vasopressin and histamine systems in specific hypothalamic areas of the rat and support the hypothesis of a role of brain histamine on the central control of water balance.

Animals↗
PubMed1984

Vasopressin, oxytocin and neurophysins in the human brain and spinal cord.

The concentrations of arginine vasopressin, oxytocin, and their related neurophysins were compared in many areas of postmortem human brain and spinal cord using specific radioimmunoassays. In the hypothalamus the ratio of vasopressin to oxytocin was approximately 3:1, and in the extrahypothalamic areas of the brain the greatest amount of both peptides was present in the locus coeruleus, and to a lesser extent the periaqueductal grey. Vasopressin only was found in the substantia nigra, and globus pallidus. In the medulla, including the nucleus of the solitary tract, the dorsal nucleus of the vagus, and the nucleus of the spinal tract of the trigeminal nerve, the amount of oxytocin was greater than that of vasopressin. In the spinal cord oxytocin predominated over vasopressin to an even greater extent, and reached particularly high values in certain segments of the intermediolateral grey column and dorsal horn. Estrogen-stimulated and nicotine-stimulated neurophysins (ESN and NSN) were both found in large amounts in those areas of the brain and spinal cord where the concentrations of the nonapeptides were greatest, but when the molar ratios of ESN to oxytocin and NSN to vasopressin were compared there was an excess of ESN.

Adult↗
PubMed1986

Septal release of vasopressin in response to osmotic, hypovolemic and electrical stimulation in rats.

The central release of vasopressin was studied in anesthetized rats using push-pull perfusions and radioimmunoassay of the hormone. A basal release was observed in the lateral septum and in the lateral ventricle, whereas no vasopressin was detected in the perfusates from the caudate nucleus. Under osmotic stimulation, vasopressin release increased up to 12 and 60 times basal levels following i.p. injections of 5 ml and 10 ml/kg b.wt. of 2 M NaCl, respectively. This increase was blocked by using a calcium-free perfusion medium containing 0.1 mM EGTA. In the lateral ventricle, osmotic stimulation (5 ml/kg of 2 M NaCl i.p.) had the same effect as in the septum. In the caudate nucleus, no release was observed. Hemorrhage also increased the septal release of vasopressin in 5 out of 6 animals tested. Electrical stimulation of the pituitary stalk and of the supraoptic nucleus was used to evoke the release of vasopressin into the bloodstream. Septal release slightly decreased during pituitary stalk stimulation, whereas it did increase during stimulation of the supraoptic region. Our results show that systemic stimuli for vasopressin release evoke both a peripheral and a septal release of the hormone. The dissociation of the effects of electrical stimulation of the pituitary stalk and of the supraoptic nucleus suggests, however, that the vasopressinergic neurones responsible for septal release are distinct from those which project to the neurohypophysis.

Animals↗
PubMed1987

Microinjection of anti-vasopressin serum into limbic structures of the rat brain: effects on passive avoidance responding and on local catecholamine utilization.

Rats which had received bilateral microinjections of 1:50 diluted anti-vasopressin serum into the dorsal or ventral hippocampus, immediately after the learning trial of a one-trial passive avoidance test, showed a reduction in avoidance latency scores during subsequent retention tests 24 and 48 h later. Postlearning microinjection of anti-vasopressin serum into either the dorsolateral septum or the caudate nucleus was without effect on the retention of passive avoidance behavior. Microinjection of anti-vasopressin serum 1 h before the 24-h retention session into either the dorsal hippocampus, the ventral hippocampus or the dorsolateral septum attenuated avoidance responding during both the 24-h and 48-h retention sessions, whereas preretention microinjection of the serum into the caudate nucleus was not effective. Intracerebroventricular administration of the anti-vasopressin serum in amounts similar to those used in the microinjection experiments did not affect retention scores when given either immediately after the learning trial or before the first retention session. One week after the behavioral experiments, a repeated microinjection of anti-vasopressin serum decreased the local alpha-methyl-p-tyrosine methylester (alpha-MPT)-induced disappearance of noradrenaline in the ventral hippocampus and the dorsal hippocampus respectively. Microinjection of the antiserum in the dorsolateral septum enhanced noradrenaline disappearance in this brain region. No effect was found on alpha-MPT-induced dopamine disappearance in the caudate nucleus following local microinjection of anti-vasopressin serum.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1987

Somatostatin centrally inhibits vasopressin secretion during haemorrhage.

Somatostatin is a hypothalamic inhibiting factor which has been reported to be involved in the regulation of the secretion of several anterior pituitary hormones. To determine if somatostatin plays a role in the control of vasopressin secretion from the posterior pituitary, we examined the effects of intracerebroventricular infusion of somatostatin-14 and a super-active analogue, cyclo-(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe), on the concentration of plasma vasopressin in response to haemorrhage in conscious sheep. Haemorrhage (15 ml/kg over 15 min) elevated plasma vasopressin. Treatment with either somatostatin-14 or the analogue inhibited the elevation of plasma vasopressin induced by haemorrhage. The inhibition may result from an effect of somatostatin on neurotransmitter afferent inputs to the hypothalamus which trigger vasopressin release during haemorrhage. Our study demonstrates for the first time that somatostatin administered centrally inhibits vasopressin secretion during haemorrhage in the conscious animal.

Animals↗
PubMed1988

Role of somatostatin in the regulation of vasopressin secretion.

Intracerebroventricular (i.c.v.) administration of somatostatin-28 (SS-28) (30 ng-1 micrograms) resulted in a dose-dependent elevation of plasma concentrations of vasopressin. Continuous i.c.v. infusion of SS-28 produced a depletion of vasopressin-like immunoactivity within the paraventricular and supraoptic of the hypothalamus as determined by immunocytochemistry. To evaluate the role of endogenous brain somatostatin in the regulation of vasopressin secretion, animals were treated with cysteamine. Cysteamine (90 mg/kg) treatment given s.c. produced a 50% depletion of endogenous brain somatostatin-like peptide concentrations. Pretreatment of animals with cysteamine attenuated hemorrhage-induced elevation of plasma vasopressin levels. The elevation of plasma vasopressin concentrations following the i.v. administration of hypertonic saline or the i.c.v. administration of angiotensin-II were not altered by cysteamine treatment. These results are consistent with the conclusion that an endogenous brain somatostatin may be involved in the physiologic regulation of vasopressin secretion following hemorrhage.

Animals↗
PubMed1988

The vasopressin gene is expressed prior to regulation in the supraoptic nuclei of fetal rats.

The development of the regulation of vasopressin (prepropressophysin) mRNA in the supraoptic nuclei (SON) of rats was studied using quantitative in situ hybridization. On day 21 of gestation, vasopressin mRNA levels in the SON were increased by osmotic stimulation, with significant positive correlation between vasopressin mRNA levels and plasma osmolality. On day 19 of gestation, vasopressin mRNA levels in the SON were not significantly increased by osmotic stimulation, and no correlation between vasopressin mRNA levels and plasma osmolality was noted. The results suggest that the mechanisms for osmotic regulation of vasopressin mRNA levels develop between days 19 and 21 of gestation, a time course consistent with the initiation of afferent innervation of the SON.

Animals↗
PubMed1993

Colocalization of calbindin-D28k with vasopressin in hypothalamic cells of the rat: a double-labeling immunofluorescence study.

By use of a double-labeling immunofluorescence method, we examined whether vasopressin-containing cells possess a calcium-binding protein, calbindin-D28k, in the hypothalamus of the rat. Subpopulations of vasopressin-containing cells varied in their ability to possess calbindin-D28k immunoreactivity in different regions. In the supraoptic nucleus, most vasopressin-immunoreactive cells were also stained for calbindin-D28k. By contrast, in the magnocellular part of the hypothalamic paraventricular nucleus, all vasopressin-labeled cells lacked calbindin-D28k. In the suprachiasmatic nucleus, no calbindin-D28k was found in vasopressin-stained cells. This study shows a further characterization of vasopressin-containing cells of the rat hypothalamus.

Animals↗
PubMed1995

Effects of gender on the central actions of neuropeptide Y and norepinephrine on vasopressin and blood pressure in the rat.

Neuropeptide Y (NPY) and norepinephrine are co-localized in the noradrenergic projection from the A1 nucleus of the medulla to the vasopressinergic magnocellular neurons of the supraoptic and paraventricular nuclei. Because this pathway is involved in the control of vasopressin release, we have examined the possibility that NPY and norepinephrine interact in this control. Because the stimulation of vasopressin release by the intracerebroventricular (i.c.v.) administration of norepinephrine is greater in male than in female rats, the experiments were carried out in conscious male rats and in female rats in the proestrous and non-proestrous phases of the estrous cycle. NPY (940 pmol i.c.v.) caused small sustained increases in plasma vasopressin concentrations that were greater in proestrous than in non-proestrous females and males. Norepinephrine i.c.v. increased plasma vasopressin levels transiently and to a greater extent in females than males. When NPY and norepinephrine were given together, the pattern of the vasopressin response was similar to that of norepinephrine alone. The magnitude of this response in males and proestrous females did not differ from that to norepinephrine alone; in non-proestrous females the response was twice that to norepinephrine alone. In non-proestrous rats, NPY also enhanced the pressor response to norepinephrine. Thus, NPY interacts centrally with norepinephrine in vasopressin release and cardiovascular function and this effect is dependent upon gender and phase of the estrous cycle.

Animals↗
PubMed1990

Immunoreactive vasopressin in end stage renal failure.

Patients with end stage renal failure have been shown to have higher basal concentrations of plasma arginine vasopressin than subjects with normal renal function. Immunoreactive vasopressin was detected in plasma from patients with severe chronic renal failure and a healthy subject at an elution volume identical to that previously determined with synthetic vasopressin. Assay of all fractions yielded identical chromatograms in the renal failure and healthy control groups. We conclude that the plasma immunoreactive vasopressin in end stage renal failure plasma coelutes with synthetic vasopressin and that the elevated concentrations found in these patients are not due to non-specific depression of binding in the vasopressin radioimmunoassay by circulating substances in renal failure.

Adult↗
PubMed1980

Antidiuretic agonism and antagonism of some O-alkylated analogues of vasopressin containing 2-O-alkylated tyrosine.

A series of 2-O-alkylated tyrosine analogues of lysine-vasopressin and desamino-lysine and arginine-vasopressin were synthesized and tested for antidiuretic activity in the water-loaded anaesthetized rat. The analogues displayed only weak antidiuretic activities. When they were infused in the rats together with lysine vasopressin it was found that 1-deamino-[2-O-ethyltyrosine]-lysine-vasopressin inhibited the vasopressin-induced antidiuretic response. The antagonistic properties were further evaluated in long-term experiments on conscious non-hydrated rats with implanted minipumps. The analogues inhibited the vasopressin-induced antidiuresis at antagonist:agonist ratios of 0.5 and 1.0.

Alkylation↗
PubMed1985

Clonidine can lower blood pressure by inhibiting vasopressin release.

The effect of clonidine on vasopressin release was studied in chloralose anesthetized rats which were made hypertensive by bilateral electrolytic lesions of the nucleus tractus solitarii (NTS). NTS lesions elevated arterial pressure and plasma vasopressin levels, and both of these variable were returned toward baseline values by intravenous injection of clonidine (30 micrograms/kg). Furthermore, the ability of a vasopressin antagonist to lower arterial pressure in NTS hypertensive rats was markedly attenuated by clonidine treatment. In contrast, autonomic blockade (chlorisondamine, 2.5 mg/kg) in NTS lesioned rats did not reduce plasma vasopressin levels or the effect of the vasopressin antagonist on blood pressure. These data demonstrate that part of the antihypertensive effect of clonidine in NTS hypertensive rats is due to inhibition of vasopressin release into the circulation.

Animals↗
PubMed1994

Sex differences in nitric oxide-mediated attenuation of vascular reactivity to vasopressin are abolished by gonadectomy.

In the rat thoracic aorta, contractile responses to vasopressin are two-fold higher in females than in males, primarily because nitric oxide-mediated attenuation of contraction is greater in males than in females. To determine the role of the gonadal steroids in this phenomenon, the effects of gonadectomy on nitric oxide and vascular reactivity to vasopressin were examined in thoracic aortae of age-matched intact and gonadectomized male and female rats. Maximal response to vasopressin was markedly higher in gonadectomized-male than in intact-male aortae (2729 +/- 421 vs. 1375 +/- 222 mg/mg ring weight; P < 0.01). Inhibition of nitric oxide synthase with NG-methyl-L-arginine (L-NMMA, 250 microM) enhanced maximal response of intact-male (2824 +/- 413 mg/mg ring weight; P < 0.01) but not gonadectomized-male aortae (3034 +/- 365 mg/mg ring weight; P > 0.05). Sensitivity of male aortae to vasopressin was unaffected by gonadectomy or L-NMMA. Maximal contraction to vasopressin did not differ between gonadectomized-female and intact-female aortae (4003 +/- 180 vs. 4645 +/- 212 mg/mg ring weight; P > 0.05). L-NMMA increased the sensitivity but not the maximal response to vasopressin in intact-female and gonadectomized-female aortae. In contrast, maximal response to phenylephrine was similar in gonadectomized-male and intact-male aortae (3843 +/- 175 vs. 4234 +/- 206 mg/mg ring weight; P > 0.05); L-NMMA enhanced maximal tension more in gonadectomized-male than in intact male aortae (4645 +/- 206 vs. 4612 +/- 176 mg/mg ring weight). Maximal contraction to phenylephrine was substantially higher in gonadectomized-female than in intact-female aortae (4303 +/- 104 vs. 3341 +/- 155 mg/mg ring weight; P < 0.001); L-NMMA enhanced maximal tension more in intact-female than in gonadectomized-female aortae (5073 +/- 158 vs. 4788 +/- 140 mg/mg ring weight). These results strongly suggest that the gonadal steroids exert important regulatory effects on nitric oxide release in the rat aorta, which are vasoconstrictor-specific and appear to involve basal and/or agonist-stimulated nitric oxide release.

Acetylcholine↗
PubMed1986

Phorbol esters and diacylglycerol inhibit vasopressin-induced increases in cytoplasmic-free Ca2+ and 45Ca2+ efflux in Swiss 3T3 cells.

Vasopressin increased intracellular free calcium concentration [Ca2+]i in quin-2-loaded quiescent Swiss 3T3 cells. This effect of vasopressin was rapidly inhibited by biologically active tumour promoters including phorbol dibutyrate (PBt2) and by the synthetic diacylglycerol 1-oleoyl-2-acetyl-glycerol (OAG). Prolonged pretreatment of Swiss 3T3 cells with PBt2 causes a loss of protein kinase C activity (Rodriguez-Pena & Rozengurt, Biochem biophys res commun 120 (1984) 1053) [28]. This pretreatment abolished the inhibition by PBt2 or OAG of vasopressin-mediated increases in [Ca2+]i. Vasopressin also stimulated 45Ca2+ efflux from cells pre-loaded with the isotope. This effect of the hormone was also inhibited by PBt2. Prolonged pretreatment with PBt2 prevented the inhibition of vasopressin-stimulated 45Ca2+ release by PBt2. Thus, protein kinase C stimulation inhibits vasopressin-mediated increases in [Ca2+]i and 45Ca2+ efflux apparently by blocking the increased release of Ca2+ from an intracellular store caused by the hormone. These findings suggest that activation of protein kinase C may act as a feedback inhibitor to modulate ligand-mediated increases in [Ca2+]i.

Animals↗
PubMed1991

Intestinal vascular sensitivity to vasopressin in portal hypertensive rats.

The intestinal vascular responsiveness to arginine vasopressin was evaluated in rats with chronic portal hypertension. Male Sprague-Dawley rats were made portal hypertensive by stenosis of the portal vein. Ten to twelve days after the induction of chronic portal hypertension, the responsiveness of the small intestinal circulation to cumulative doses of vasopressin was evaluated using an isolated pump-perfused small intestinal preparation. The ED50 for maximal vasoconstriction was increased twofold in portal hypertensive rats compared with control rats. To determine if the impaired responsiveness to arginine vasopressin was related to the hyperglucagonemia of chronic portal hypertension, plasma glucagon levels were elevated in normal rats to levels previously measured in portal hypertensive rats (i.e. approximately 450 pg/mL), and the dose response studies were repeated. Glucagon significantly attenuated the responsiveness of the intestinal vasculature to vasopressin. Equipotent doses of nitroprusside also attenuated intestinal vascular responsiveness to vasopressin. The results indicate that there is a reduced vascular sensitivity to vasopressin in the intestine of portal hypertensive animals and suggest that elevations in circulating vasodilators in portal hypertensive conditions may partially explain this altered vascular responsiveness.

Animals↗